<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04653506</url>
  </required_header>
  <id_info>
    <org_study_id>0368-20-TLV</org_study_id>
    <nct_id>NCT04653506</nct_id>
  </id_info>
  <brief_title>Paracetamol / Ibuprofen for Postpartum Pain in the Early Postpartum Period</brief_title>
  <official_title>Non - Opioid Treatments (Single Administration) for Pain During the Early Postpartum Period After Vaginal Delivery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tel-Aviv Sourasky Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tel-Aviv Sourasky Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will examine the effectiveness of non-opioid analgesia (Paracetamol versus&#xD;
      Ibuprofen) in the early postpartum period&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Postpartum pain is a common problem that leads to difficulties in basic daily activities,&#xD;
      overuse of opioid medications, and even impaired breastfeeding ability. Non-opioid analgesia&#xD;
      may play an essential role in reducing pain and improving the postpartum period including the&#xD;
      ability to breastfeed and caring for the newborn.&#xD;
&#xD;
      This study will compare non-opioid treatment - 1000 mg Paracetamol versus 400 mg Ibuprofen in&#xD;
      order to determine the optimal pain relief treatment in the early postpartum period that may&#xD;
      decrease the use of opioid analgesia.&#xD;
&#xD;
      The investigators will evaluate the pain by the Numerical Rating Scale (NRS) index in the&#xD;
      early postpartum period. The evaluation will conduct at 4-time points - while the women&#xD;
      taking the pain relief (time 0), an hour later (time 1), 4, and 6 hours later (time 4 and&#xD;
      time 6).&#xD;
&#xD;
      The investigators will compare the analgetic effect of each drug and evaluate the need for&#xD;
      additional analgesia whether opioid or not.&#xD;
&#xD;
      Furthermore, the investigators will examine when women sought pain relief and whether pain&#xD;
      relief contributes to the ability of Breastfeeding.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 28, 2020</start_date>
  <completion_date type="Anticipated">November 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 28, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Women participating in the study will receive postpartum analgesia immediately while reporting pain requiring analgesia (NRS &lt;3)&#xD;
Pain Reliefs will be given in a double-blind mechanism, in closed envelopes&#xD;
The envelopes will contain Paracetamol 1000 mg or Ibuprofen 400 mg&#xD;
Women participating in the study will answer a questionnaire to characterize the pain while taking the pain relief (time 0), an hour later (time 1), 4 and 6 hours later (time 4 and time 6)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>The primary investigator will be the only one to have the information about envelopes contain</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Pain relief after treatment with Paracetamol or Ibuprofen</measure>
    <time_frame>6 hours after intervention</time_frame>
    <description>After getting a pain relief treatment, the participants will answer a questionnaire about pain relief at 4 - time points: the time of getting the pain relief treatment (time 0), after an hour (time 1), 4 hours (time 4), and six hours (time 6). The pain rating will be on the Numeric Rating Scale (NRS) that labeled from zero (no pain) to ten ((worst pain).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum pain location</measure>
    <time_frame>6 hours after intervention</time_frame>
    <description>After getting a pain relief treatment, the participants will answer a questionnaire about pain relief at 4 - time points: the time of getting the pain relief treatment (time 0), after an hour (time 1), 4 hours (time 4), and six hours (time 6). The questionnaire will describe the maximal pain location area and the effectiveness of analgesic treatment in this area (by rating the pain on the NRS). The questionnaire will be at the time of taking the pain relief treatment (time 0), after an hour (time 1), 4 hours (time 4), and six hours (time 6)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Effect on breastfeeding</measure>
    <time_frame>6 hours after intervention</time_frame>
    <description>The participants will answer a questionnaire that will describe the effect of' pain relief on a woman's ability to breastfeed. The questionnaire will ask their desire to breastfeed before giving birth, did they really manage to breastfeed, and when they started breastfeeding. The investigator will describe if there is a correlation between pain relief and the ability to breastfeed.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Paracetamol group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women who were treated with a double-blind mechanism in an envelope containing paracetamol pills (1000 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ibuprofen group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women who were treated with a double-blind mechanism in an envelope containing Ibuprofen pills (400 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol 1000 mg</intervention_name>
    <description>Women participating in the study will receive postpartum analgesia immediately while reporting pain requiring analgesia, by envelope contains paracetamol 1000 mg or ibuprofen 400 mg</description>
    <arm_group_label>Paracetamol group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen 400 mg</intervention_name>
    <description>Women participating in the study will receive postpartum analgesia immediately while reporting pain requiring analgesia, by envelope contains paracetamol 1000 mg or ibuprofen 400 mg</description>
    <arm_group_label>Ibuprofen group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women between the ages of 18-50, who gave birth in a vaginal birth&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Sensitivity to Paracetamol or Ibuprofen&#xD;
&#xD;
          -  After cesarean section&#xD;
&#xD;
          -  Received analgesia prior to study recruitment&#xD;
&#xD;
          -  Perineal tears grade 3 \ 4&#xD;
&#xD;
          -  Women with chronic pain, rheumatic disease, fibromyalgia, or trauma&#xD;
&#xD;
          -  Women with a diagnosis or medication for anxiety or depression&#xD;
&#xD;
          -  Dropout for women whose newborns needed respiratory support with intubation, cooling,&#xD;
             prolonged hospitalization in NICU exceeding one week&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Postpartum women</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>shai ram, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tel Aviv Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shai Ram, MD</last_name>
    <phone>972 0506337159</phone>
    <email>shairam85@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sharon Maslovitz, MD</last_name>
    <phone>972527360048</phone>
    <email>MASLOVITZ@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tel Aviv Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>shai ram, MD</last_name>
      <phone>+972506337159</phone>
      <email>shairam85@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Sharon Maslovitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shai Ram, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Macarthur AJ, Macarthur C. Incidence, severity, and determinants of perineal pain after vaginal delivery: a prospective cohort study. Am J Obstet Gynecol. 2004 Oct;191(4):1199-204.</citation>
    <PMID>15507941</PMID>
  </reference>
  <reference>
    <citation>Fahey JO. Best Practices in Management of Postpartum Pain. J Perinat Neonatal Nurs. 2017 Apr/Jun;31(2):126-136. doi: 10.1097/JPN.0000000000000241.</citation>
    <PMID>28277399</PMID>
  </reference>
  <reference>
    <citation>Eisenach JC, Pan PH, Smiley R, Lavand'homme P, Landau R, Houle TT. Severity of acute pain after childbirth, but not type of delivery, predicts persistent pain and postpartum depression. Pain. 2008 Nov 15;140(1):87-94. doi: 10.1016/j.pain.2008.07.011. Epub 2008 Sep 24.</citation>
    <PMID>18818022</PMID>
  </reference>
  <reference>
    <citation>Peahl AF, Dalton VK, Montgomery JR, Lai YL, Hu HM, Waljee JF. Rates of New Persistent Opioid Use After Vaginal or Cesarean Birth Among US Women. JAMA Netw Open. 2019 Jul 3;2(7):e197863. doi: 10.1001/jamanetworkopen.2019.7863. Erratum in: JAMA Netw Open. 2019 Aug 2;2(8):e1911235.</citation>
    <PMID>31348508</PMID>
  </reference>
  <reference>
    <citation>Deussen AR, Ashwood P, Martis R. Analgesia for relief of pain due to uterine cramping/involution after birth. Cochrane Database Syst Rev. 2011 May 11;(5):CD004908. doi: 10.1002/14651858.CD004908.pub2. Review. Update in: Cochrane Database Syst Rev. 2020 Oct 20;10:CD004908.</citation>
    <PMID>21563142</PMID>
  </reference>
  <reference>
    <citation>Wuytack F, Smith V, Cleary BJ. Oral non-steroidal anti-inflammatory drugs (single dose) for perineal pain in the early postpartum period. Cochrane Database Syst Rev. 2016 Jul 14;7:CD011352. doi: 10.1002/14651858.CD011352.pub2. Review. Update in: Cochrane Database Syst Rev. 2021 Jan 11;1:CD011352.</citation>
    <PMID>27412362</PMID>
  </reference>
  <reference>
    <citation>Davies NM. Clinical pharmacokinetics of ibuprofen. The first 30 years. Clin Pharmacokinet. 1998 Feb;34(2):101-54. Review.</citation>
    <PMID>9515184</PMID>
  </reference>
  <reference>
    <citation>Chou D, Abalos E, Gyte GM, GÃ¼lmezoglu AM. Paracetamol/acetaminophen (single administration) for perineal pain in the early postpartum period. Cochrane Database Syst Rev. 2013 Jan 31;(1):CD008407. doi: 10.1002/14651858.CD008407.pub2. Review.</citation>
    <PMID>23440827</PMID>
  </reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 22, 2020</study_first_submitted>
  <study_first_submitted_qc>November 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2020</study_first_posted>
  <last_update_submitted>December 11, 2020</last_update_submitted>
  <last_update_submitted_qc>December 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tel-Aviv Sourasky Medical Center</investigator_affiliation>
    <investigator_full_name>Eli Sprecher, MD</investigator_full_name>
    <investigator_title>director head of clinical trails department, principal investigator, clinical professor</investigator_title>
  </responsible_party>
  <keyword>Post Partum Pain, Pain Relief, Non-Opioids Analgesia</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

